Please login to the form below

Not currently logged in
Email:
Password:

FasT CAR-T

This page shows the latest FasT CAR-T news and features for those working in and with pharma, biotech and healthcare.

Gracell Bio developing faster, cheaper CAR-T production

Gracell Bio developing faster, cheaper CAR-T production

The company's 'FasT CAR-T' only requires eight days to complete the production process, which is made up of the one day of manufacturing plus seven days for releasing tests, ... Without support from patients, their families, and clinical scientists, we

Latest news

  • Janssen’s CAR-T gains PRIME status in Europe Janssen’s CAR-T gains PRIME status in Europe

    EMA fast-track could help Janssen close gap. Janssen has been granted a valuable PRIME (Priority Medicines) designation from the European Medicines Agency for its CAR-T candidate for multiple myeloma, ... The CAR-T therapy would complement Janssen's

  • Gilead strikes deal with NHS England on CAR-T Yescarta Gilead strikes deal with NHS England on CAR-T Yescarta

    NHS England claims adult leukaemia access is first in Europe. NHS England has agreed a market access deal with Gilead for its groundbreaking CAR-T therapy Yescarta, and is claiming it ... It is likely that we are only beginning to see the benefits that

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • New models of NHS care – new models of pharma response? New models of NHS care – new models of pharma response?

    Most notably, fast patient access for CAR-T cell therapies, Gilead’s Yescarta and Novartis’ Kymriah, where England has been ahead of its European counterparts in making the drugs available. ... CAR-T therapies are cost-effective for these patients,

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Health

OPEN Health is a family of expert practices, working in partnership to drive positive change in healthcare communications & market...

Latest intelligence

The ALS patient journey
Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape
Dr Tyler Ray, OPEN Health Medical Communications...
Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...

Infographics